Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2025 | $15.00 → $16.00 | Sell → Neutral | Citigroup |
| 6/30/2023 | $22.00 → $21.00 | Neutral → Sell | Citigroup |
| 4/18/2023 | $21.50 | Neutral → Underperform | BofA Securities |
| 1/9/2023 | Underperform → Neutral | BofA Securities | |
| 10/7/2022 | $24.00 → $17.00 | Sell → Neutral | Citigroup |
| 9/26/2022 | $20.00 | Equal-Weight → Underweight | Morgan Stanley |
| 4/18/2022 | $19.50 → $21.30 | Neutral → Underweight | Piper Sandler |
| 1/18/2022 | $32.00 → $30.00 | Equal-Weight | Morgan Stanley |
REVENUE OF $121.8 MILLION, DOWN 12% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $1.9 MILLION; EX-ITEMS, $6.6 MILLION, DOWN 58% SEQUENTIALLY AND 44% YEAR-OVER-YEARGAAP LOSS PER SHARE OF $0.02; EPS EX-ITEMS OF $0.06, DOWN 72% SEQUENTIALLY AND 58% YEAR-OVER-YEARFREE CASH FLOW OF $0.5 MILLIONNET DEBT INCREASED BY $3.9 MILLION; LEVERAGE RATIO AT 1.20COMPANY REPURCHASED 51,781 SHARES OF COMMON STOCK, FOR $0.9 MILLION AGGREGATE PURCHASE PRICECOMPANY ANNOUNCES Q2 2026 QUARTERLY DIVIDENDHOUSTON, April 29, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported first quarter 2026 revenue of $121,800,000. Core's operating income was $1,900,0
FIRST QUARTER 2026 EARNINGS WEBCAST AT 7:30 A.M. CDT / 8:30 A.M. EDT ON APRIL 30, 2026HOUSTON, March 23, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority.At this time, due to regional instability, including client-driven project delays, travel const
FOURTH QUARTER REVENUE OF $138.3 MILLION, UP 3% SEQUENTIALLY AND UP 7% YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $15.8 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEARFOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF OVER 11%, DOWN 100 BASIS POINTS SEQUENTIALLY AND 80 BASIS POINTS YEAR-OVER-YEARFOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.21, DOWN 4% SEQUENTIALLY AND YEAR-OVER-YEARFOURTH QUARTER FREE CASH FLOW OF $5.1 MILLIONNET DEBT REDUCED BY $1.2 MILLION; LEVERAGE RATIO IMPROVED TO 1.09COMPANY REPURCHASED 363,207 SHARES OF COMMON STOCK, FOR $5.7 MILLION AGGREGATE PURCHASE PRICECOMPANY ANNOUNCES Q1 2026 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $526.5 MILLI
Citigroup upgraded Core Labs from Sell to Neutral and set a new price target of $16.00 from $15.00 previously
Citigroup downgraded Core Labs from Neutral to Sell and set a new price target of $21.00 from $22.00 previously
BofA Securities downgraded Core Labs from Neutral to Underperform and set a new price target of $21.50
SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
SD - Core Laboratories Inc. /DE/ (0001958086) (Filer)
8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
REVENUE OF $121.8 MILLION, DOWN 12% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $1.9 MILLION; EX-ITEMS, $6.6 MILLION, DOWN 58% SEQUENTIALLY AND 44% YEAR-OVER-YEARGAAP LOSS PER SHARE OF $0.02; EPS EX-ITEMS OF $0.06, DOWN 72% SEQUENTIALLY AND 58% YEAR-OVER-YEARFREE CASH FLOW OF $0.5 MILLIONNET DEBT INCREASED BY $3.9 MILLION; LEVERAGE RATIO AT 1.20COMPANY REPURCHASED 51,781 SHARES OF COMMON STOCK, FOR $0.9 MILLION AGGREGATE PURCHASE PRICECOMPANY ANNOUNCES Q2 2026 QUARTERLY DIVIDENDHOUSTON, April 29, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported first quarter 2026 revenue of $121,800,000. Core's operating income was $1,900,0
FIRST QUARTER 2026 EARNINGS WEBCAST AT 7:30 A.M. CDT / 8:30 A.M. EDT ON APRIL 30, 2026HOUSTON, March 23, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority.At this time, due to regional instability, including client-driven project delays, travel const
FOURTH QUARTER REVENUE OF $138.3 MILLION, UP 3% SEQUENTIALLY AND UP 7% YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $15.8 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEARFOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF OVER 11%, DOWN 100 BASIS POINTS SEQUENTIALLY AND 80 BASIS POINTS YEAR-OVER-YEARFOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.21, DOWN 4% SEQUENTIALLY AND YEAR-OVER-YEARFOURTH QUARTER FREE CASH FLOW OF $5.1 MILLIONNET DEBT REDUCED BY $1.2 MILLION; LEVERAGE RATIO IMPROVED TO 1.09COMPANY REPURCHASED 363,207 SHARES OF COMMON STOCK, FOR $5.7 MILLION AGGREGATE PURCHASE PRICECOMPANY ANNOUNCES Q1 2026 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $526.5 MILLI
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)